Showing posts with label heart disease. Show all posts
Showing posts with label heart disease. Show all posts

Thursday, March 28, 2013

Stem Cell Therapy for Heart Disease - Jim Parker Attorney at Law and former Texas State Legislature Member

Stem Cell Therapy for Heart Failure Patient - Jim ParkerJim Parker, Attorney at Law is a former Texas State Legislature member who was treated with umbilical-cord derived stem cells for heart disease at the Stem Cell Institute in Panama in March 2011.

Jim was kind enough to answer some questions about his condition before and after treatment. He also discusses his trip to Panama, the clinic and its staff.

What is your diagnosis and when were you diagnosed?

Exactly what my diagnosis was I cannot say in medical terms. Factually speaking, I had five (5) by-passes in 1995 (or thereabouts) and then had nine (9) stents added over the next 13 or 14 years. I began to experience severe angina in January and February of 2011 and was hospitalized in February with a series of heart attacks. I had consulted my cardiologist in Abilene and had also gone to a cardiologist in Dallas who was supposed to be really good. They both told me that there was simply nothing else I could do. When I was released from the local hospital in early March of 2011, my family doctor gave me a bottle of morphine and a bottle of nitroglycerine and basically told me to make it as well as I could for as long as I could.

We had heard about the Panama operation (Stem Cell Institute) from local people who had gone for various reasons. Every one of them seemed well-pleased with the results they were able to get. After release from the local hospital in early March of 2011, I sent my medical records to Panama and arranged an appointment in mid-March. I traveled to Panama in a wheel chair because I was not able to walk in the airport.
Upon arrival in Panama the first day was spent drawing my blood for blood tests. The next 7 days the (umbilical cord-derived) stem cells were infused back into my body.

I found the staff to be very helpful and apparently knowledgeable. Our needs outside the clinic were well taken care of and we were very satisfied with our experience.

I steadily improved after Panama to the point where I have now resumed a normal life (at as normal as a 68 year-old guy can expect) and I am back at work. I have not had to use a nitroglycerine pill in over a year and, so far as I can tell, I have no immediate heart problems and but for the damage suffered from my earlier episodes, my heart would be in good shape. My longtime cardiologist will still see me but he believes Panama was some sort of voodoo and I have just been lucky. I continue to take a mild blood pressure medication and I do still take blood thinner. However, about 6 months after Panama my blood pressure got so low they had to cut down the strength of the medication.

What symptoms did you have before you cam for treatment?

Prior to Panama I had a series of heart attacks over a number of years and was eating nitroglycerine tablets like M&Ms.

Which treatments did you try in the U.S. first, and when did you know that you needed to find help outside of the country?

I tried every treatment available in the US of A. Had every test know to man. I mean 5 by-passes and 9 stents many not be a record but it has to be well beyond average.

Why did you choose The Stem Cell Institute in Panama for stem cell treatment?

I chose the Stem Cell Institute in Panama because several local folks had gone there and they were pleased with the results. And, I really had no place to go but the cemetery.

How were the doctors at the clinic? How were the facilities?

The only doctor I recall seeing was Dr. Paz. The facilities were at least on par with what you would find in the US and the staff was more solicitous and helpful than you would find in the US.

How are your symptoms now? How have they improved?

I have no symptoms now. (Knock on wood). I have some breathing issues but I am told that is COPD and it is not really all that bad. I could live another 100 years feeling as good as I do now.

Have you reduced or eliminated any of the medications you were taking before stem cell therapy?

I have cut way back on medication I was using prior to Panama and feel I could probably cut back some more; however, I have to give the local MD's something to work on. And, by the way, I go to the doctor as little as possible now. Maybe twice a year at most.

How soon did you start seeing/noticing a difference? How was your overall experience?

I began to notice a difference (maybe it was just anticipation) about 6 to 8 weeks after returning from Panama. It has gotten better and better since then. Since I can move around, I have lost over 40 pounds and now am at 6 feet tall and 215 pounds, down from over 250 pounds.

How has this changed your life?

Panama did not exactly change my life. It literally gave my life back to me. I have been married to the same woman for over 50 years and we were able to become intimate again. I am out and about every day and pretty much do what I want to do and go where I want to go.

Additional Comments

Many people should know about this option. There are people dying here in the land of the free and the home of the brave each day that are in better shape than I was when I went to Panama.

And, by the way, I am not subject to flights of fancy and accepting things a thinking person might not accept. I hold a doctor of jurisprudence degree and have been a criminal defense attorney all my adult life. I am about as cynical and skeptical as you will find but I am a believer in your process.

Thank you,

Jim Parker

Tuesday, March 12, 2013

Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic

Leo Bockeria, Vladimir Bogin, Olga Bockeria, Tatyana Le, Bagrat Alekyan, Erik J Woods, Amalia A Brown, Thomas E Ichim and Amit N Patel

Journal of Translational Medicine 2013, 11:56 doi:10.1186/1479-5876-11-56
Published: 5 March 2013


Heart failure is one of the key causes of morbidity and mortality world-wide. The recent findings that regeneration is possible in the heart have made stem cell therapeutics the Holy Grail of modern cardiovascular medicine. The success of cardiac regenerative therapies hinges on the combination of an effective allogeneic “off the shelf” cell product with a practical delivery system. In 2007 Medistem discovered the Endometrial Regenerative Cell (ERC), a new mesenchymal-like stem cell. Medistem and subsequently independent groups have demonstrated that ERC are superior to bone marrow mesenchymal stem cells (MSC), the most widely used stem cell source in development. ERC possess robust expansion capability (one donor can generate 20,000 patients doses), key growth factor production and high levels of angiogenic activity. ERC have been published in the peer reviewed literature to be significantly more effect at treating animal models of heart failure (Hida et al. Stem Cells 2008).Current methods of delivering stem cells into the heart suffer several limitations in addition to poor delivery efficiency. Surgical methods are highly invasive, and the classical catheter based techniques are limited by need for sophisticated cardiac mapping systems and risk of myocardial perforation. Medistem together with Dr. Amit Patel Director of Clinical Regenerative Medicine at University of Utah have developed a novel minimally invasive delivery method that has been demonstrated safe and effective for delivery of stem cells (Tuma et al. J Transl Med 2012). Medistem is evaluating the combination of ERC, together with our retrograde delivery procedure in a 60 heart failure patient, double blind, placebo controlled phase II trial. To date 17 patients have been dosed and preliminary analysis by the Data Safety Monitoring Board has allowed for trial continuation.The combined use of a novel “off the shelf” cell together with a minimally invasive 30 minute delivery method provides a potentially paradigm-shifting approach to cardiac regenerative therapy.

http://www.translational-medicine.com/content/11/1/56/abstract

Monday, January 14, 2013

Medistem Inc. Annual Letter to Shareholders

SAN DIEGO, CA–(Marketwire – Jan 4, 2013) – Medistem Inc. ( PINKSHEETS : MEDS ) today issues the following letter to shareholders.

Dear Fellow Shareholders,

2012 was marked by significant progress in the development of the Endometrial Regenerative Cell (ERC), our new universal donor “stem cell drug.” Most significantly, we initiated a double blind, placebo controlled clinical study in patients with end stage heart failure, in which ERC were administered via the Medistem’s patent-pending minimally invasive procedure. The clinical trial comprises three escalating doses of ERC with cohorts of 20 patients per dose. To date 14 patients have been treated with no adverse effects, thus demonstrating feasibility of the administration procedure, as well as safety of the cells. Because it is a double blind study, efficacy will not be known until the trial is completed. The clinical trial is being conducted at the Backulev Center for Cardiovascular Surgery in Moscow, Russia, by Academician Leo Bockeria. The company also initiated a 15 patient critical limb ischemia trial in China in collaboration with Shanghai Jia Fu Medical Apparatus Inc. To date two patients have been treated. The trial is based on the Medistem critical limb ischemia study that has been cleared by the FDA.

In addition, we licensed from Yale University the world-wide rights for a patent application using ERC to treat Type 1 diabetes. We also initiated a program in type 1 diabetes, with the goal of filing an Investigational New Drug application before the end of 2013 to allow for clinical trial initiation.

In 2012, researchers at the National Institutes of Health (NIH) independently verified and published a peer reviewed article confirming ERC possess a markedly higher expression of genes associated with new blood vessel formation and stem cell potency compared to bone marrow mesenchymal stem cells. The publication may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-207.pdf

In addition, our intellectual property was further enhanced with the issuance of patent #8,241,621 covering the use of fat derived stem cells for treatment of autoimmune conditions such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. We have also filed 2 patent applications covering the use of ERC for radiation protection and treatment of traumatic brain injury.

Also, in collaboration with several corporate and academic institutions we published a total of 7 peer reviewed papers in 2012 on collaborative breakthroughs we made in the areas of hepatitis, cancer, and prevention of transplant rejection.

Additionally, this year we added two new advisory board members including Gene Ray, Ph.D., and Alexander Gershman, M.D., Ph.D. Dr. Ray was founder of the Titan Corporation, where he served as CEO and a director of the corporation since the company’s inception in 1981. In 2011, Titan Corporation was acquired by L-3 Communications for $2.6 billion. Dr. Gershman is one of the first surgeons in the world to apply the method of laparoscopic surgery and robotic-assisted surgery to urology. He currently holds several hospital appointments, including: Director of Institute of Advanced Urology at the Cedars-Sinai Medical Center; Director of Urologic Laparoscopy in the Division of Urology, and Harbor-UCLA Medical Center.

Finally, this year marked a major transition in the leadership of the company. I was appointed to the position of CEO on October 26 and Dr. Thomas Ichim transitioned to the position of President and Chief Scientific Officer. Dr. Ichim has done an outstanding job leading the company for the past four years and I look forward to working closely with him at commercializing the ERC product.

In 2013 our objective will be to meet the following milestones:
•Return to “fully reporting” status and listing on the OTCBB
•Appointment of at least one new board member
•Initiation of the FDA cleared critical limb ischemia trial in the USA
•Completing enrollment in the RECOVER-ERC double blind cardiac trial
•Filing an IND for type 1 diabetes.

I want to end by thanking our loyal shareholders for their continued support as Medistem continues on its mission to generate the first practical “stem cell medicine.”

Sincerely Yours,

Dr. Alan Lewis
Chief Executive Officer
Medistem Inc.


About Medistem
Medistem Inc. is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.

ERCs have several distinguishing advantages to other stem cell therapies: a) Non-invasive method of collection; b) Unlimited supply of cells; isolated from menstrual blood of young healthy donors; c) Economical and scalable to manufacture; d) Exert higher therapeutic activity compared to other stem cells; and e) demonstrated safe in animal and pilot human studies.

Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.
.
.
Contact:.
.
Thomas Ichim, Ph.D.
President and Chief Scientific Officer
Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego, CA 92122
858 349 3617
www.medisteminc.com